Table 2.

Association of transmembrane protease serine 2 and v-ets erythroblastosis virus E26 oncogene homolog fusion status with clinical parameters among 669 prostate cancer samples

Parameters	Fusion		Positive rate (%)	P
	Negative (n)	Positive (n)
PCa samples	559	110	16.4
Age (year)				0.57
≤65	187	40	17.6
>65	370	70	15.9
BMI (kg m−2)				0.11
<19	12	2	14.3
19–27	447	82	15.5
>27	92	25	21.4
Sample type				0.13
Biopsy	156	23	12.8
Prostatectomy	403	87	17.8
PSA level (ng ml−1)				0.31
<4	87	13	13.0
4–10	117	29	19.9
>10	353	68	16.2
Unknown	2	0	0
Major Gleason score				0.44
3	230	52	18.4
4	254	43	14.5
5	75	15	16.7
Sum of Gleason score				0.93
6	94	18	16.1
3+4	129	31	19.4
4+3	76	14	15.6
>7	260	47	15.3
Clinical tumor stage				0.79
T0/T1	115	25	17.9
T2	287	53	15.6
T3	100	17	14.5
T4	24	6	20.0
Unknown	33	9	21.4
Perineural invasion				0.67
Positive	197	44	18.3
Negative	203	41	16.8
Unknown	159	25	13.6
Lymphovascular invasion				0.55
Positive	38	7	15.6
Negative	183	44	19.4
Unknown	182	36	16.5
Biochemical recurrence				0.70
Positive	21	4	16.0
Negative	257	51	16.6
Lost	125	32	20.4

BMI: body mass index; PSA: prostate-specific antigen; TMPRSS2-ERG: transmembrane protease serine 2 and v-ets erythroblastosis virus E26 oncogene homolog; PCa: prostate cancer